GlassScriptPhysician profile
Aaron Dickinson
NPI 1528564820
$1,175.82
in general payments reported to CMS, 2019-2025
14 companies · $52.10 in 2025
The $52.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $12.67 · 2021: $236 · 2022: $214 · 2023: $313 · 2024: $64.93 · 2025: $52.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $463.16 | 2019-2021 | |
| Novo Nordisk INC | $241.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $86.21 | 2019-2022 | |
| Lilly USA, LLC | $74.20 | 2022-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $60.28 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.05 | 2022-2023 | |
| Bausch Health US, LLC | $45.22 | 2022 | |
| Abbvie INC. | $32.34 | 2023 | Vraylar |
| Almatica Pharma LLC | $31.44 | 2024 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $23.42 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $18.65 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $17.29 | 2022 | |
| Dexcom, INC. | $16.13 | 2023 | Dexcom G6 Transmitter |
| Celgene Corporation | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Dickinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.